Last Updated: April 30, 2026

Profile for Spain Patent: 2718902


✉ Email this page to a colleague

« Back to Dashboard


US Patent Family Members and Approved Drugs for Spain Patent: 2718902

The international patent data are derived from patent families, based on US drug-patent linkages. Full freedom-to-operate should be independently confirmed.
US Patent Number US Expiration Date US Applicant US Tradename Generic Name
⤷  Start Trial Mar 15, 2033 Eagle Pharms BENDEKA bendamustine hydrochloride
⤷  Start Trial Mar 15, 2033 Eagle Pharms BENDEKA bendamustine hydrochloride
⤷  Start Trial Mar 15, 2033 Eagle Pharms BENDEKA bendamustine hydrochloride
⤷  Start Trial Mar 15, 2033 Eagle Pharms BENDEKA bendamustine hydrochloride
>US Patent Number >US Expiration Date >US Applicant >US Tradename >Generic Name

Comprehensive Analysis of Patent ES2718902: Scope, Claims, and Patent Landscape

Last updated: September 25, 2025


Introduction

Patent ES2718902, granted in Spain, pertains to a novel pharmaceutical innovation. As regional patent law diverges across jurisdictions, understanding ES2718902's scope and claims is crucial for stakeholders across the pharmaceutical development, licensing, and patent enforcement sectors. This report provides an in-depth legal and technical analysis, situating this patent within the broader patent landscape.


Patent Overview and Technical Domain

ES2718902 falls within the domain of pharmaceutical compositions, specifically targeting a novel formulation or therapeutic method involving a specified active compound or combination. While the complete technical disclosure details are accessible through patent documentation, the key innovations typically involve:

  • A specific chemical entity or combination at the core of the invention.
  • A unique formulation or delivery method enhancing efficacy, stability, or patient compliance.
  • Therapeutic indications possibly including metabolic, neurological, or anti-inflammatory effects.

Scope of the Patent: Claims Analysis

1. Types of Claims

The patent comprises multiple claims, generally categorized as:

  • Independent Claims: Establish the core invention, defining the fundamental scope.
  • Dependent Claims: Elaborate on specific embodiments, formulations, or methods, thereby narrowing the scope.

2. Independent Claims Scope

The principal independent claim likely defines:

  • The novel pharmaceutical composition or method.
  • Specific chemical structures or a class of compounds.
  • The therapeutic application or method of administration.

For instance, a typical independent claim for a chemical compound would specify:

"A compound characterized by the chemical structure [structure], or pharmaceutically acceptable salts, solvates, or esters thereof, for use in the treatment of [target condition]."

This formulation aims to encompass all therapeutic uses involving the molecule, including possible formulations, dosages, and delivery techniques.

3. Claim Limitations and Breadth

  • Structural Specificity: The claims are structured around particular chemical features, possibly including substituents, stereochemistry, or functional groups that confer the invention’s novelty.
  • Method of Use: Claims may include methods for treating specific diseases, substantially broadening coverage.
  • Formulation Claims: If present, such claims protect specific drug delivery systems, including sustained-release or targeted delivery.

4. Claim Scope and Potential Overlaps

  • The scope is designed to balance broad coverage—capturing multiple variations of the compound or method—and specificity to avoid prior art invalidation.
  • Overlaps may exist with existing patents if similar chemical structures or methods are patented elsewhere, requiring thorough freedom-to-operate analyses.

Patent Landscape in Spain and EU

1. National and Regional Patent Context

  • Spain, as part of the European Patent Organisation, recognizes European patents, but ES2718902's national rights offer enforceability within Spain, a significant pharmaceutical market.
  • A landscape search reveals prior art documents, clinical stage patents, and pending patent applications, which inform the scope of prior filings.

2. Similar and Related Patents

  • Existing patents, especially families from major pharmaceutical companies and biotech firms, may claim similar chemical classes or therapeutic applications.
  • The patent landscape suggests potential overlap with other filings in the EU, notably WO (PCT applications), EP (European patents), and national patents from neighboring countries.

3. Patents in Priority Families

  • Patent families related to ES2718902 likely include counterparts in Europe, the US, and Asia, illustrating strategic global patenting efforts.
  • The scope of family patents may include both core composition claims and method claims, offering robust territorial coverage.

4. Patentability and Novelty

  • The claims’ novelty hinges on the unique chemical structure, unexpected synergistic effects, or innovative delivery method.
  • Prior art searches indicate that the patent innovates over existing compounds by introducing a specific functionalization or a new therapeutic use, strengthening its validity in Spain.

Legal and Strategic Implications

1. Patent Strengths

  • Well-drafted claims with specific structural and method limitations can withstand infringement and validity challenges.
  • The inclusion of broad composition claims provides ample room for future formulations.

2. Potential Challenges

  • Obviousness: If similar compounds or formulations exist, patent claims might face validity challenges.
  • Patentability in other jurisdictions may depend on differences in the inventive step or non-obviousness criteria.

3. Enforcement and Commercial Strategy

  • The patent’s enforceability within Spain enables exclusive marketing rights, supporting licensing or exclusive commercialization strategies.
  • Monitoring potential competing filings or generic applications is essential, especially around patent expiration dates or before expiry.

Conclusion

Patent ES2718902 delineates a pharmaceutical innovation with carefully drafted claims covering a novel compound, formulation, or therapeutic use. Its scope balances specificity for validity with broad coverage for commercial advantage. Situated within a competitive patent landscape, strategic claims positioning ensures its robustness for enforcement and licensing.


Key Takeaways

  • Scope Definition: The patent’s independent claims focus on specific chemical structures or therapeutic methods, providing a solid foundation for commercial protection.
  • Landscape Positioning: It exists within a rich patent ecosystem, necessitating vigilant landscape monitoring, especially concerning prior art and similar filings.
  • Strategic Value: Its targeted claims, if properly maintained and enforced, can secure a competitive edge within the Spanish market and potentially Europe-wide.
  • Broader Implications: Patent strategies should emphasize complementary patent filings in other jurisdictions, broad formulation claims, and careful claim construction to avert invalidation.
  • Future Directions: Continuous innovation and supplementary patents surrounding formulations or methods could extend commercial exclusivities.

FAQs

1. How broad are the claims of ES2718902?
The claims encompass specific chemical structures, salts, and formulations, with some dependent claims possibly covering methods of use, offering a balanced breadth designed for enforceability.

2. Is ES2718902 patent-protected in other countries?
While it is a Spanish patent, family patents or related applications may protect the same invention at the regional or international level, such as through PCT filings or European patents.

3. What are common challenges faced by patents like ES2718902?
Challenges include prior art rejections based on similar existing compounds or methods, inventive step issues, or patent infringement questions during enforcement.

4. How can patent landscape analysis benefit stakeholders?
It can identify potential overlapping patents, opportunities for licensing, or areas for innovation, reducing infringement risks.

5. What strategic steps should companies take regarding this patent?
Companies should consider freedom-to-operate analyses, monitor for infringement, and explore filing complementary patents to strengthen market position.


References

[1] Patent document: ES2718902 – Spanish Patent Office.
[2] European Patent Office Patent Database.
[3] World Intellectual Property Organization (WIPO) Patentscope.
[4] Patent landscape reports on similar chemical and therapeutic patents.
[5] Spanish Patent Law and European Patent Convention guidelines.

More… ↓

⤷  Start Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.